Apeloa Pharmaceutical Co.,Ltd (SHE:000739)
China flag China · Delayed Price · Currency is CNY
18.81
+0.02 (0.11%)
Apr 28, 2026, 3:05 PM CST

SHE:000739 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
9,4459,72811,95711,44010,5068,910
Other Revenue
55.4855.4865.3533.9239.132.44
9,5019,78412,02211,47410,5458,943
Revenue Growth (YoY)
-17.77%-18.62%4.77%8.81%17.92%13.49%
Cost of Revenue
6,9537,2989,2258,6218,0756,579
Gross Profit
2,5482,4862,7962,8532,4702,364
Selling, General & Admin
947.05971.421,1211,125985.33906.43
Research & Development
576.41611.17641.47624.87532.92446.22
Other Operating Expenses
66.435.3812.7623.331.7633.05
Operating Expenses
1,6011,6081,7851,7751,5631,405
Operating Income
946.53877.831,0121,078906.8959.39
Interest Expense
-27.92-24.65-32.2-43.77-59.23-35.72
Interest & Investment Income
90.25131.7892.17113.4775.83165.7
Currency Exchange Gain (Loss)
-25.51-25.5158.3838.1393.42-23.09
Other Non Operating Income (Expenses)
-34.61-1.822.18-23.85-5.38-3.58
EBT Excluding Unusual Items
948.74957.621,1321,1621,0111,063
Gain (Loss) on Sale of Investments
-1.88--10.13-21.7-82.61-23.62
Gain (Loss) on Sale of Assets
8.849.030.281.331.370.28
Asset Writedown
-0.19-5-8.37--4.67-7.95
Other Unusual Items
111.03104.5589.2263.2386.5282.67
Pretax Income
1,0671,0661,2031,2051,0121,114
Income Tax Expense
175.16175.52172.44149.3422.89158.53
Earnings From Continuing Operations
891.38890.681,0311,055989.17955.55
Minority Interest in Earnings
-0.23-00.270.030-
Net Income
891.15890.681,0311,055989.17955.55
Net Income to Common
891.15890.681,0311,055989.17955.55
Net Income Growth
-13.98%-13.62%-2.30%6.69%3.52%17.00%
Shares Outstanding (Basic)
1,1501,1531,1631,1691,1741,179
Shares Outstanding (Diluted)
1,1501,1531,1631,1691,1741,179
Shares Change (YoY)
-1.11%-0.86%-0.52%-0.40%-0.38%-0.00%
EPS (Basic)
0.770.770.890.900.840.81
EPS (Diluted)
0.770.770.890.900.840.81
EPS Growth
-13.01%-12.87%-1.78%7.12%3.91%17.00%
Free Cash Flow
990.34833.99748.01400.9817-90.18
Free Cash Flow Per Share
0.860.720.640.340.70-0.08
Dividend Per Share
0.5860.5860.3560.3170.2970.285
Dividend Growth
64.68%64.68%12.35%6.70%4.21%17.28%
Gross Margin
26.81%25.41%23.26%24.86%23.42%26.43%
Operating Margin
9.96%8.97%8.42%9.39%8.60%10.73%
Profit Margin
9.38%9.10%8.58%9.20%9.38%10.69%
Free Cash Flow Margin
10.42%8.52%6.22%3.49%7.75%-1.01%
EBITDA
1,6331,5401,5761,6311,2961,318
EBITDA Margin
17.19%15.74%13.11%14.21%12.29%14.74%
D&A For EBITDA
686.68662.17564.15553.06389.43358.64
EBIT
946.53877.831,0121,078906.8959.39
EBIT Margin
9.96%8.97%8.42%9.39%8.60%10.73%
Effective Tax Rate
16.42%16.46%14.33%12.40%2.26%14.23%
Revenue as Reported
9,5019,78412,02211,47410,5458,943
Advertising Expenses
-9.3511.299.671.611.86
Source: S&P Global Market Intelligence. Standard template. Financial Sources.